Praneeth Sudalagunta
Overview
Explore the profile of Praneeth Sudalagunta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bishop R, Li T, Sudalagunta P, Nasr M, Nyman K, Alugubelli R, et al.
Haematologica
. 2024 Dec;
PMID: 39633543
Multiple myeloma (MM) patients are often refractory to targeted therapies including proteasome inhibitors (PIs). Here, analysis of RNA sequencing data derived from 672 patients with newly diagnosed or relapsed/refractory disease...
2.
Burger K, Fernandez M, Meads M, Sudalagunta P, Oliveira P, Canevarolo R, et al.
Cancer Res
. 2023 Sep;
83(23):3901-3919.
PMID: 37702657
Significance: CK1δ and CK1ε are attractive therapeutic targets in multiple myeloma whose expression increases with disease progression and connote poor outcomes, and that are necessary to sustain expression of genes...
3.
Jiang Q, Sudalagunta P, Silva M, Canevarolo R, Zhao X, Ahmed K, et al.
Bioinformatics
. 2022 Jun;
38(16):4002-4010.
PMID: 35751591
Motivation: Time-lapse microscopy is a powerful technique that relies on images of live cells cultured ex vivo that are captured at regular intervals of time to describe and quantify their...
4.
Mostofa A, Distler A, Meads M, Sahakian E, Powers J, Achille A, et al.
JCI Insight
. 2021 Nov;
6(24).
PMID: 34793338
The clinical utility of histone/protein deacetylase (HDAC) inhibitors in combinatorial regimens with proteasome inhibitors for patients with relapsed and refractory multiple myeloma (MM) is often limited by excessive toxicity due...
5.
Sudalagunta P, Silva M, Canevarolo R, Alugubelli R, DeAvila G, Tungesvik A, et al.
EBioMedicine
. 2020 Apr;
54:102716.
PMID: 32268267
Background: Multiagent therapies, due to their ability to delay or overcome resistance, are a hallmark of treatment in multiple myeloma (MM). The growing number of therapeutic options in MM requires...
6.
Silva A, Silva M, Sudalagunta P, Distler A, Jacobson T, Collins A, et al.
Cancer Res
. 2017 Apr;
77(12):3336-3351.
PMID: 28400475
Multiple myeloma remains treatable but incurable. Despite a growing armamentarium of effective agents, choice of therapy, especially in relapse, still relies almost exclusively on clinical acumen. We have developed a...